Literature DB >> 28710676

Hypertriglyceridemia, an Underestimated Cardiovascular Risk Factor: An Epidemiological Study of the Rome Area.

Roberto Volpe1, Giulio Nati2, Alberto Chiriatti3, Massimo Sabatini2, Fabio Valente3.   

Abstract

INTRODUCTION: Hypertriglyceridemia (triglycerides ≥200 mg/dL) is a major cardiovascular risk factor. Despite the high incidence of this condition in the Italian population, epidemiological information remains limited. AIM: To analyze a large database of clinical charts from general practitioners in the Rome area of Italy.
METHODS: In this study, the DATAMEG database of patients treated in the Rome area between 2000 and 2015 was analyzed. The database was searched for information on (1) all patients diagnosed with hypertriglyceridemia, (2) all prescriptions for the treatment of hypertriglyceridemia, and (3) all patients who had an acute myocardial infarction.
RESULTS: The overall prevalence of hypertriglyceridemia was 4.4% (3647/82,595). Among patients followed from January 1, 2015 onwards, 2786/55,345 (5.0%) were diagnosed with hypertriglyceridemia. Of these, 418 (15.0%) received at least one prescription of triglyceride-lowering treatment. Over the same period, 1653 patients had at least three measurements of triglycerides ≥200 mg/dL, with only 357 (21.6%) receiving at least one prescription of triglyceride-lowering drugs in the year following the last measurement. Furthermore, 513 patients had at least one measurement of ≥500 mg/dL. Of these, only 246 (48.0%) received at least one prescription of triglyceride-lowering drugs in the year following the last measurement. In total, 3485 patients had an acute myocardial infarction (prevalence, 4.3%) in 2015. Of these, only 288 (8.3%) received at least one prescription of triglyceride-lowering drugs in the year following this event.
CONCLUSION: These findings confirmed a pattern of inadequate treatment of hypertriglyceridemia in the Rome area.

Entities:  

Keywords:  Epidemiological study; Hypertriglyceridemia; Lipid lowering treatment; Myocardial infarction

Mesh:

Substances:

Year:  2017        PMID: 28710676     DOI: 10.1007/s40292-017-0222-3

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  10 in total

Review 1.  Long chain omega-3 fatty acids and cardiovascular disease: a systematic review.

Authors:  Javier Delgado-Lista; Pablo Perez-Martinez; Jose Lopez-Miranda; Francisco Perez-Jimenez
Journal:  Br J Nutr       Date:  2012-06       Impact factor: 3.718

Review 2.  Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement.

Authors:  Maciej Banach; Tomas Stulc; Ricardo Dent; Peter P Toth
Journal:  Int J Cardiol       Date:  2016-09-26       Impact factor: 4.164

3.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Authors:  Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano; Marie-Therese Cooney
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

4.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

Review 5.  Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.

Authors:  Uchechukwu K Sampson; Sergio Fazio; MacRae F Linton
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

Review 6.  Safety considerations with fibrate therapy.

Authors:  Michael H Davidson; Annemarie Armani; James M McKenney; Terry A Jacobson
Journal:  Am J Cardiol       Date:  2006-12-08       Impact factor: 2.778

7.  Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.

Authors:  Nadeem Sarwar; John Danesh; Gudny Eiriksdottir; Gunnar Sigurdsson; Nick Wareham; Sheila Bingham; S Matthijs Boekholdt; Kay-Tee Khaw; Vilmundur Gudnason
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

Review 8.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Authors:  M John Chapman; Henry N Ginsberg; Pierre Amarenco; Felicita Andreotti; Jan Borén; Alberico L Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Børge G Nordestgaard; Kausik K Ray; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen; Gerald F Watts
Journal:  Eur Heart J       Date:  2011-04-29       Impact factor: 29.983

Review 9.  Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.

Authors:  Alexander Tenenbaum; Robert Klempfner; Enrique Z Fisman
Journal:  Cardiovasc Diabetol       Date:  2014-12-04       Impact factor: 9.951

Review 10.  A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids.

Authors:  Dean G Karalis
Journal:  Adv Ther       Date:  2016-12-15       Impact factor: 3.845

  10 in total
  1 in total

1.  Ferrari Corporate Wellness Program: Results of a Pilot Analysis and the "Drag" Impact in the Workplace.

Authors:  Alessandro Biffi; Fredrick Fernando; Paolo Emilio Adami; Michele Messina; Felice Sirico; Fernando Di Paolo; Roberta Coluccia; Claudio Borghi; Flavio D'Ascenzi; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.